Profusa, Inc., a commercial stage digital health company, announced the successful closing of its business combination with NorthView Acquisition Corp., a special purpose acquisition company. This transaction paves the way for Profusa's common stock to commence trading on Nasdaq under the ticker symbol "PFSA" starting July 14, 2025. The move marks a significant milestone in Profusa's mission to advance its pioneering tissue-integrating biosensors platform, designed for continuous biochemical monitoring and improved chronic disease management. The company expressed excitement about the potential impact of becoming a public entity on its ability to enhance healthcare solutions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northview Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-065686), on July 18, 2025, and is solely responsible for the information contained therein.